Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.
about
An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)Cytotoxic granule secretion by lymphocytes and its link to immune homeostasisMaking sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromesSystematic review: macrophage activation syndrome in inflammatory bowel diseaseImmunosuppression after sepsis: systemic inflammation and sepsis induce a loss of naïve T-cells but no enduring cell-autonomous defects in T-cell functionChimeric antigen receptor-modified T cells for acute lymphoid leukemia[Hemophagocytic lymphohistiocytosis : A diagnostic challenge on the ICU].Unexpected thrombocytopenia and anemia in cynomolgus monkeys induced by a therapeutic human monoclonal antibody.Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosisPathophysiology of Pediatric Multiple Organ Dysfunction Syndrome.Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.Salmonella enterica infection stimulates macrophages to hemophagocytoseA novel model for IFN-γ-mediated autoinflammatory syndromes.Increased ferroportin-1 expression and rapid splenic iron loss occur with anemia caused by Salmonella enterica Serovar Typhimurium infection in miceSustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO MiceProinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice.IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis.Novel Insights into Interleukin 6 (IL-6) Cis- and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex.Increased ribonuclease expression reduces inflammation and prolongs survival in TLR7 transgenic mice.Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?Toll-like receptor 9 and interferon-γ receptor signaling suppress the B-cell fate of uncommitted progenitors in miceAdoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment.Salmonella Infection Enhances Erythropoietin Production by the Kidney and Liver, Which Correlates with Elevated Bacterial BurdensTLR9-mediated inflammation drives a Ccr2-independent peripheral monocytosis through enhanced extramedullary monocytopoiesis.How We Manage Hyperferritinemic Sepsis-Related Multiple Organ Dysfunction Syndrome/Macrophage Activation Syndrome/Secondary Hemophagocytic Lymphohistiocytosis Histiocytosis.Safety, tolerability, and biomarkers of the treatment of mice with aerosolized Toll-like receptor ligands.Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome.Not all hemophagocytes are created equally: appreciating the heterogeneity of the hemophagocytic syndromes.Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.Advances in understanding the pathogenesis of HLH.Macrophage activation syndrome and cytokine-directed therapies.Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis.Genetic defects in cytolysis in macrophage activation syndrome.Hereditary and acquired hemophagocytic lymphohistiocytosis.Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.Clinical features and correct diagnosis of macrophage activation syndrome.HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis.
P2860
Q26751532-FCB75355-B9BB-4DC6-A446-0838B56C1B7CQ26776499-CB6F94F7-0E24-4072-8809-97C6FB2802F8Q27011625-40C79BFA-CE8E-4BC1-B52B-DD412A8AF91FQ27025349-F3F6A188-26FF-47A6-B5E0-867C4EFDE17FQ27320494-49157CA0-CDC7-400C-98D6-7714FFF85804Q29620130-59075A80-5924-4BFF-B229-B4DFEDEDA60BQ30245507-CC9AE372-4370-4F1B-AB8E-06B46CE70B69Q33406359-43997A70-CBC8-4FB0-BBD4-9CF109741F12Q33429617-C380A1C0-D1AD-43E9-8D9A-B164948DB3CEQ33439759-F55ACED5-3C07-4FD5-A27F-566AB7CAE103Q34269827-12FDC23E-E50F-4D90-88F0-FE503C81C8EEQ35072142-FB79D80B-10D7-4F8F-BF35-D9D847BA81F2Q35110844-2DDDF0AC-4DFF-4C09-99E7-A8065C253356Q35609338-59B301A6-8D11-4CD9-A5FB-9D3B617CE086Q35804806-9E785DA5-B6B6-455C-A376-68BCECDF0432Q35889971-D82B772D-6601-49F2-914A-BB8693E7B5C5Q35935473-84E6A204-1467-4422-815C-B1538804BE2CQ36041225-10396478-6D4F-4C37-94E0-E702B5F49076Q36245985-9036A892-3ED1-46F5-9AAA-1BFD51B9E851Q36283919-D54357EC-D349-4800-B900-FD3734478335Q36675017-59BC3B03-788D-42FE-B661-292E0F5DBB13Q36925790-EC8A39E5-9139-44FC-B158-FD38C2F5F571Q37019912-C7FC5A5F-8672-4224-B0A4-BBE58C7C2361Q37257207-9399408D-540A-42EF-927A-E352D809ED7AQ37277020-003B4F7A-3149-40B1-9402-306567DAD118Q37287154-F15045AD-D73F-4553-AD78-FB433B1C4E2CQ37305022-DE169CF5-B7A8-4A29-A437-05F84CE3714AQ37387929-59203946-F2D0-47ED-8F84-B8CAEA18723AQ37558881-A6000CF8-2494-4C4E-9441-55726CD1508CQ37589316-D8C6E492-644E-4CEE-9FC9-1656F5530000Q37956870-B25CC33E-994E-489E-A915-FF84D9E8C8A1Q37993678-383FACBA-6B84-49B0-A323-EE0903078422Q38098232-572C7E21-0411-481F-BB23-0DDFC7FD32E4Q38224085-8EBF9DF4-586E-4CB1-8661-9D59FB77741BQ38229212-3BABDE67-B9A3-4871-952A-74797C9076C3Q38236321-45D2301E-EB6B-45FD-AA38-D9B400F304AFQ38259614-89D1DC02-605F-4EC0-A5C2-B59A328A1121Q38267068-BC803D36-E6F6-4F50-BE9E-27DBDD75A323Q38530013-37A8E055-A26D-4DE1-A2BA-250EDA9D266DQ38599138-A6D7BFED-5488-40F3-BEC5-05B5EA4E137E
P2860
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.
@ast
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.
@en
type
label
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.
@ast
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.
@en
prefLabel
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.
@ast
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.
@en
P2093
P2860
P356
P1476
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice
@en
P2093
Edward M Behrens
Gary A Koretzky
Katharine Slade
Michele Paessler
Portia A Kreiger
Sheila Rao
Taku Kambayashi
P2860
P304
P356
10.1172/JCI43157
P407
P577
2011-05-16T00:00:00Z